PPARgamma: none is more

A team from Scripps Florida and the Dana-Farber Cancer Institute has developed peroxisome proliferation-activated receptor-g-binding compounds that have potent antidiabetic activity but do not actually agonize the receptor and thus lack the side effects commonly associated with the target.¹ The researchers have founded Adipothermics Inc., with backing from Third Rock Ventures, to advance the new class of compounds into the clinic.

Peroxisome proliferation-activated receptor-g (PPARG; PPARg) agonists marketed to treat type 2 diabetes include GlaxoSmithKline plc's Avandia rosiglitazone and Takeda Pharmaceutical Co. Ltd.'s Actos pioglitazone. The insulin sensitizers posted 2010 sales of $677 million and $4.7 billion, respectively.²...